C. J. C. de Haas

This study identifies WTA-specific IgM as a critical immune factor for human protection against S. aureus, outperforming IgG in opsonophagocytic activity and correlating with clinical outcomes.

This paper shows that modifying anti-capsular antibodies to enhance hexamerization improves complement activation and immune protection against Streptococcus pneumoniae.

This study shows that C9 polymerization enhances MAC pore-mediated bacterial killing and is impaired in complement-resistant strains.

This study shows that C1r2s2 proteases stabilize C1q binding to surface-bound IgG, with subclass-specific effects and improved phagocytosis with hexamer-enhanced IgGs.

This study investigates how different glycosylation patterns on Staphylococcus aureus cell walls affect langerin recognition and Langerhans cell activation, finding that β-GlcNAc is sufficient for langerin binding regardless of its position on WTA.

This study shows Staphylococcal protein A inhibits IgG hexamer formation, blocking complement activation, but IgG3 can still induce complement activation despite SpA.

This study evaluates CHIPS as a therapeutic agent for inflammation, showing promise in mice but safety concerns in humans due to pre-existing antibodies.

This study shows SSL13 activates neutrophils through FPR2, acting as a chemoattractant and inducer of degranulation and oxidative burst, differing from other SSLs that inhibit immune responses.